

LA JOLLA CANCER RESEARCH FOUNDATION

ANIMAL USAGE FORM



AUF 1413

1. PRINCIPAL INVESTIGATOR

WAYNE A. BORDER, M.D.

OFFICE PHONE

226

HOME/EMERGENCY PHONE

(714) 770-4602

2. OTHER INVESTIGATOR

LUCIA LAGUINO, PH.D.

230

539-0609

3. SENIOR TECHNICIAN

4. PROJECT NAME

ANTI-HUMAN TGF β CYCLIZED PEPTIDE

5. GRANT NUMBER, IF ANY

250200

NEW

RENEWAL

PILOT

PROJECT NUMBER

K

6. START DATE

END DATE

MICE

RATS

RABBITS

CPI

OTHER SPECIES

QUANTITY:

2

7. PROJECT GOALS (SEE INSTRUCTIONS)

To produce quantities of anti-human TGF β cyclized peptide for use in kidney disease research.

8. RATIONALE (SEE INSTRUCTIONS)

Rabbits produce high quality antiserum which can be used for identification of human TGF β in tissue samples and in vitro assays to study progression of kidney injury.

9. DESCRIBE USE OF ANIMALS (SEE INSTRUCTIONS)

All injections/bleedings to be performed by animal care facility personnel.

1. Pre-bleeding 20 ml from ear vein.
2. Inject 50 μ g TGF β cyclized purified peptide (0.5 mL antigen in PBS + 0.5 mL FCA) subcutaneously in 2 sites.
3. After one month, boost with 125 μ g antigen (0.25 mL antigen in PBS + 0.25 mL incomplete adjuvant) subcutaneously, 2 sites.
4. After 10 days, bleed 50 ml from alternating ear veins 3 times.
5. Repeat steps 3-4 at 4-6 week intervals.

RESEARCH PROTOCOL
IN THIS
SECTION
DESCRIBE
THE
PROTOCOL
TO BE USED
IN THIS
RESEARCH PROTOCOL

10. PAIN LEVEL

A B C

IF B OR C READ INSTRUCTIONS. PROVIDE DESCRIPTION OR JUSTIFICATION HERE

CONFIDENTIAL

11. EUTHANASIA (SEE INSTRUCTIONS)

DURING PROJECT
END OF PROJECT

METHOD
OR
TECHNIQUE

CQ.
Q.Q.

CERV. DISLOC.
OTHER SPECIES

RETAIN CARCASSSES YES
NO


12. SIGNATURES

1 WA Border

DATE U2 05334 DATE

AF
MCA

DATE



ANIMAL PROCEDURE REQUEST

or procedures to be performed by Animal Facility personnel) return this form to the Animal Facility Office.

LJCRF

TODAY'S DATE.

Principal Investigator E. ROSENTHAL

Lueia f. Lançado

Phone . . . Lab No. . .

230

Lab No.

1

This procedure relates to the project outlined on Annex A usage form No.

date or dates on which this procedure is required (please allow 7 days for scheduling):

12/13 188 50 w (if more) 5

12/16/88

req(ire) (attach) a) b)

Extn 1204 (Second form)

卷之三

Describe the procedure(s) required:

101. of blood to be collected each procedure:

m1:

1

RECEIVED

MAP 15 2004

— 1 —



Injection of 2 rabbits with Linear FP-103 peptide
no 86-82 from TGF β .


2 " with Glycylized FP-103 " .
no 88-83

~~coupling~~

Procedure: 2 mg / rabbit of each peptide.

- 2 mg peptide were dissolved in 250 μ l DDM
(add to the solution to couple the peptide)
- 0.5 mg Methylated BSA were ~~mixed~~ ~~coupled~~
~~coupling agent~~
(Sigma A1009 : H₂BSA)
- volume 3 ml
- Added 250 μ l Freud's adjuvant complete.
- mixed 1 h with homogenizer.
- 0.5 ml solution was injected in each rabbit.

Note: Both peptides were difficult to dissolve.
they were not fully purified



Injection of 2 ml/min linear TGF β peptide

Cyclic

PG peptide

Procedure

except Friend's incomplete adjuvant was used

For mice: KLH-peptides were already coupled
It only need to F.i. dose 14 μ g
Inject 0.5 ml

Prob-7, m^o 1286 for PG = A1, F1, 85
1285